Improved Care, Survival for ESRD in Patients With Multiple Myeloma
Incidence of renal replacement therapy for treatment of end-stage renal disease in multiple myeloma has decreased in the last decade.
Incidence of renal replacement therapy (RRT) for treatment of end-stage renal disease (ESRD) in patients with multiple myeloma has decreased in the last decade, and there have been clinically meaningful improvements in survival among these patients, according to a study published in the Journal of the American Society of Nephrology.1
In a retrospective cohort study, researchers led by Scott Reule, MD, of the University of Minnesota evaluated temporal trends from 2001 to 2010 in order to identify patients with ESRD from multiple myeloma treated with RRT through the United States Renal Data System database.
RELATED: Impact of Trisomies on Multiple Myeloma Prognosis Investigated
They found that demography-adjusted incidence ratios of ESRD from multiple myeloma decreased between 2001 and 2002 as well as 2009 and 2010 in the overall population.
Mortality rates were found to be 86.7, 41.4, and 34.4 per 100 person-years in the first 3 years of RRT, respectively, compared to 32.3, 20.6, and 21.3 in a matched control group without multiple myeloma.
These findings were similar when adjusted for demographic characteristics, comorbidity markers, and laboratory test values.
- Reule S, Sexton DJ, Solid CA, et al. ESRD due to Multiple Myeloma in the United States, 2001–2010 [published online ahead of print October 29, 2015]. J Am Soc Nephrol. doi: 10.1681/ASN.2014090876.